MedTrace Logo

School-based Program for the Prevention of Rheumatic Heart Disease in Endemic Regions

NCT06720272 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6000

Last updated 2026-01-20

No results posted yet for this study

Summary

The overall objective of the PREVENT trial is to evaluate the effectiveness of an integrated, school-based program for the prevention of rheumatic heart disease (RHD) in regions with an endemic pattern of RHD.

We conduct a stepped wedge cluster randomized trial in randomly selected schools in Nepal and Zambia.

The intervention will be delivered at the level of the school and consists in the introduction of a dedicated school-nurse program providing health care through education about RHD, assessment, intervention, and follow-up of GABHS pharyngitis, and facilitation of secondary antibiotic prophylaxis for children with RHD.

Conditions

  • Rheumatic Heart Disease in Children

Interventions

OTHER

School nurse program

The intervention consists in the introduction of a school-nurse program providing health care through education about rheumatic heart disease, assessment, intervention, and follow-up of group A beta-hemolytic streptococcal pharyngitis, and facilitation of secondary antibiotic prophylaxis for children with rheumatic heart disease.

Sponsors & Collaborators

  • Centre for Infectious Disease Research in Zambia (CIDRZ)

    collaborator UNKNOWN

  • National Academy of Medical Sciences, Nepal

    collaborator OTHER_GOV

  • University of Oxford

    collaborator OTHER

  • Thomas Pilgrim

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
5 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-15
Primary Completion
2028-02-29
Completion
2028-02-29

Countries

  • Nepal
  • Zambia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06720272 on ClinicalTrials.gov